Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

MarketWatch was able to verify Zeng's claims via videos and was also able to order delivery of Ozempic to an address in China. The price was 798 yuan ($108) for a one-month supply that is injected ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk's (NYSE:NVO) was ...

US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24, ...

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...